Partially based on our in vivo work, avapritinib is now approved in the clinic for the treatment of advanced GIST with the specific PDGFRA p.D842V mutation (Gebreyohannes et al., 2019b). The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.